{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:39Z","timestamp":1792784919797,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SA was supported by the K\u00f6ln Fortune Programm, CECAD-Rotationsprogramm and KFH-Stiftung."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autosomal Dominant Polycystic Kidney Disease is the most common genetic cause of kidney failure. Outcome prediction is essential to guide therapeutic decisions. However, currently available models are of limited accuracy. We aimed to examine the potential of serum proteomics for improved risk stratification. Here we show that 29 proteins are significantly associated with yearly kidney function decline. Functional enrichment on these 29 proteins reveals GO:BP terms related to immune response, lipoproteins and metabolic processes. A comparison to an Immunoglobulin A nephropathy cohort provides information regarding the eGFR-dependency and disease specificity of these proteins. The final outcome prediction model\u00a0(adjusted R\u00b2 0.31) contains six proteins, namely Endothelial Plasminogen Activator Inhibitor (SERPINF1),\u00a0Glutathione Peroxidase 3 (GPX3), Afamin (AFM),\u00a0FERM Domain Containing Kindlin-3 (FERMT3), Complement Factor H Related 1 (CFHR1),\u00a0and Retinoic Acid Receptor Responder 2 (RARRES2), the predictive value of which is independent from the clinical and imaging parameters currently used in clinical care. The validation of these models in different cohorts indicates the accuracy of the models. It will now be important to move towards targeted validation in a prospective study.<\/jats:p>","DOI":"10.1038\/s41467-025-61887-8","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:37:58Z","timestamp":1752885478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Developing serum proteomics based prediction models of disease progression in ADPKD"],"prefix":"10.1038","volume":"16","author":[{"given":"Hande \u00d6.","family":"Aydogan Balaban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-4614","authenticated-orcid":false,"given":"Sita","family":"Arjune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-7477","authenticated-orcid":false,"given":"Franziska","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-8034","authenticated-orcid":false,"given":"Jan-Wilm","family":"Lackmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rauen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9600-7757","authenticated-orcid":false,"given":"Philipp","family":"Antczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-0745","authenticated-orcid":false,"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"61887_CR1","doi-asserted-by":"publisher","first-page":"i2","DOI":"10.1093\/ckj\/sfy103","volume":"11","author":"RU M\u00fcller","year":"2018","unstructured":"M\u00fcller, R. U. & Benzing, T. Management of autosomal-dominant polycystic kidney disease\u2014state-of-the-art. Clin. Kidney J. 11, i2 (2018).","journal-title":"Clin. Kidney J."},{"key":"61887_CR2","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1681\/ASN.2018050493","volume":"29","author":"MB Lanktree","year":"2018","unstructured":"Lanktree, M. B. et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J. Am. Soc. Nephrol. 29, 2593\u20132600 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"61887_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","volume":"60","author":"PC Harris","year":"2009","unstructured":"Harris, P. C. & Torres, V. E. Polycystic kidney disease. Annu Rev. Med. 60, 321\u2013337 (2009).","journal-title":"Annu Rev. Med."},{"key":"61887_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres, V. E., Harris, P. C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287\u20131301 (2007).","journal-title":"Lancet"},{"key":"61887_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"RU M\u00fcller","year":"2022","unstructured":"M\u00fcller, R. U. et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA working group on inherited kidney disorders, the european rare kidney disease reference network and polycystic kidney disease international. Nephrol. Dial. Transpl. 37, 825\u2013839 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"61887_CR6","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."},{"key":"61887_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. 26, 160\u2013172 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"61887_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"GallE C Le","year":"2016","unstructured":"C Le, G. allE. et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27, 942\u2013951 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"61887_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","volume":"107","author":"O Devuyst","year":"2025","unstructured":"Devuyst, O. et al. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD). Kidney Int. 107, S1\u2013239 (2025).","journal-title":"Kidney Int"},{"key":"61887_CR10","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/diagnostics13061152","volume":"13","author":"M Rroji","year":"2023","unstructured":"Rroji, M., Figurek, A. & Spasovski, G. Proteomic approaches and potential applications in autosomal dominant polycystic kidney disease and fabry disease. Diagnostics 13, 1152 (2023).","journal-title":"Diagnostics"},{"key":"61887_CR11","doi-asserted-by":"publisher","first-page":"F590","DOI":"10.1152\/ajprenal.00301.2022","volume":"324","author":"EA Houske","year":"2023","unstructured":"Houske, E. A. et al. Metabolomic profiling to identify early urinary biomarkers and metabolic pathway alterations in autosomal dominant polycystic kidney disease. Am. J. Physiol. Ren. Physiol. 324, F590\u2013F602 (2023).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"61887_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1053\/j.akdh.2022.12.009","volume":"30","author":"ASL Yu","year":"2023","unstructured":"Yu, A. S. L. & Landsittel, D. P. Biomarkers in polycystic kidney disease: are we there?. Adv. kidney Dis. Health 30, 285\u2013293 (2023).","journal-title":"Adv. kidney Dis. Health"},{"key":"61887_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100550","volume":"22","author":"P Schlosser","year":"2023","unstructured":"Schlosser, P., Grams, M. E. & Rhee, E. P. Proteomics: Progress and promise of high-throughput proteomics in chronic kidney disease. Mol. Cell Proteom. 22, 100550 (2023).","journal-title":"Mol. Cell Proteom."},{"key":"61887_CR14","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.bbagen.2012.11.020","volume":"1830","author":"R Brigelius-Floh\u00e9","year":"2013","unstructured":"Brigelius-Floh\u00e9, R. & Maiorino, M. Glutathione peroxidases. Biochim. Biophys. Acta (BBA) Gen. Subj. 1830, 3289\u20133303 (2013).","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"key":"61887_CR15","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1126\/scitranslmed.aba3613","volume":"12","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease. Sci. Transl. Med. 12, 3613 (2020).","journal-title":"Sci. Transl. Med."},{"key":"61887_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1126\/science.285.5425.245","volume":"285","author":"DW Dawson","year":"1999","unstructured":"Dawson, D. W. et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245\u2013248 (1999).","journal-title":"Science"},{"key":"61887_CR17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/prca.200780140","volume":"2","author":"X Lai","year":"2008","unstructured":"Lai, X. et al. Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients. Proteom. Clin. Appl. 2, 1140 (2008).","journal-title":"Proteom. Clin. Appl"},{"key":"61887_CR18","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1073\/pnas.1219260110","volume":"110","author":"E Goicoechea De Jorge","year":"2013","unstructured":"Goicoechea De Jorge, E. et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc. Natl. Acad. Sci. USA 110, 4685\u20134690 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61887_CR19","doi-asserted-by":"publisher","unstructured":"Agborbesong E., Li L. X., Li L., Li X. Molecular mechanisms of epigenetic regulation, inflammation, and cell death in ADPKD. Front. Mol. Biosci. https:\/\/doi.org\/10.3389\/fmolb.2022.922428 (2022).","DOI":"10.3389\/fmolb.2022.922428"},{"key":"61887_CR20","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1530\/JOE-18-0174","volume":"238","author":"G Helfer","year":"2018","unstructured":"Helfer, G. & Wu, Q. F. Chemerin: a multifaceted adipokine involved in metabolic disorders. J. Endocrinol. 238, R79 (2018).","journal-title":"J. Endocrinol."},{"key":"61887_CR21","doi-asserted-by":"publisher","first-page":"28175","DOI":"10.1074\/jbc.M700793200","volume":"282","author":"KB Goralski","year":"2007","unstructured":"Goralski, K. B. et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 282, 28175\u201328188 (2007).","journal-title":"J. Biol. Chem."},{"key":"61887_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/pr0500105","volume":"4","author":"L Jerkovic","year":"2005","unstructured":"Jerkovic, L. et al. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J. Proteome Res 4, 889\u2013899 (2005).","journal-title":"J. Proteome Res"},{"key":"61887_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nm1722","volume":"14","author":"M Moser","year":"2008","unstructured":"Moser, M., Nieswandt, B., Ussar, S., Pozgajova, M. & F\u00e4ssler, R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat. Med. 14, 325\u2013330 (2008).","journal-title":"Nat. Med."},{"key":"61887_CR24","doi-asserted-by":"publisher","first-page":"14852","DOI":"10.1074\/jbc.M112.434621","volume":"288","author":"R Hart","year":"2013","unstructured":"Hart, R., Stanley, P., Chakravarty, P. & Hogg, N. The Kindlin 3 pleckstrin homology domain has an essential role in lymphocyte function-associated antigen 1 (LFA-1) integrin-mediated B cell adhesion and migration. J. Biol. Chem. 288, 14852 (2013).","journal-title":"J. Biol. Chem."},{"key":"61887_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/ndt\/gfx304","volume":"33","author":"P Pang","year":"2018","unstructured":"Pang, P. et al. Pre-clinical model of severe glutathione peroxidase-3 deficiency and chronic kidney disease results in coronary artery thrombosis and depressed left ventricular function. Nephrol. Dial. Transplant. 33, 923\u2013934 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"61887_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10157-005-0343-1","volume":"9","author":"MA El-Far","year":"2005","unstructured":"El-Far, M. A., Bakr, M. A., Farahat, S. E. & Abd El-Fattah, E. A. Glutathione peroxidase activity in patients with renal disorders. Clin. Exp. Nephrol. 9, 127\u2013131 (2005).","journal-title":"Clin. Exp. Nephrol."},{"key":"61887_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000045293","volume":"81","author":"HE Roxborough","year":"1999","unstructured":"Roxborough, H. E., Mercer, C., McMaster, D., Maxwell, A. P. & Young, I. S. Plasma glutathione peroxidase activity is reduced in haemodialysis patients. Nephron 81, 278\u2013283 (1999).","journal-title":"Nephron"},{"key":"61887_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1006\/mgme.1998.2760","volume":"65","author":"JC Whitin","year":"1998","unstructured":"Whitin, J. C. et al. Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Mol. Genet Metab. 65, 238\u2013245 (1998).","journal-title":"Mol. Genet Metab."},{"key":"61887_CR29","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1080\/0886022X.2022.2106243","volume":"44","author":"R Szentimrei","year":"2022","unstructured":"Szentimrei, R. et al. Changes in serum pigment epithelium-derived factor levels after kidney transplantation in patients with end-stage renal disease. Ren. Fail 44, 1649 (2022).","journal-title":"Ren. Fail"},{"key":"61887_CR30","doi-asserted-by":"publisher","first-page":"E2169","DOI":"10.1210\/jc.2014-2235","volume":"99","author":"E Hui","year":"2014","unstructured":"Hui, E. et al. Elevated circulating pigment epithelium-derived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 99, E2169 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"61887_CR31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.kint.2017.03.041","volume":"92","author":"A Tortajada","year":"2017","unstructured":"Tortajada, A. et al. Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney Int. 92, 953\u2013963 (2017).","journal-title":"Kidney Int."},{"key":"61887_CR32","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","volume":"92","author":"NR Medjeral-Thomas","year":"2017","unstructured":"Medjeral-Thomas, N. R. et al. Circulating complement factor H\u2013related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int. 92, 942 (2017).","journal-title":"Kidney Int."},{"key":"61887_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3109\/0886022X.2015.1040707","volume":"37","author":"J Blaszak","year":"2015","unstructured":"Blaszak, J. et al. High serum chemerin level in CKD patients is related to kidney function, but not to its adipose tissue overproduction. Ren. Fail 37, 1033\u20131038 (2015).","journal-title":"Ren. Fail"},{"key":"61887_CR34","doi-asserted-by":"crossref","unstructured":"Kaur R. et al. Clinical significance of adropin and afamin in evaluating renal function and cardiovascular health in the presence of CKD-MBD biomarkers in chronic kidney disease.Diagnostics 13, 3158 (2023).","DOI":"10.3390\/diagnostics13193158"},{"key":"61887_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-023-09405-0","volume":"20","author":"CR Ram\u00edrez Medina","year":"2023","unstructured":"Ram\u00edrez Medina, C. R. et al. Proteomic signature associated with chronic kidney disease (CKD) progression identified by data-independent acquisition mass spectrometry. Clin. Proteom. 20, 1\u201312 (2023).","journal-title":"Clin. Proteom."},{"key":"61887_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2215\/CJN.0000000000000427","volume":"19","author":"T Bais","year":"2024","unstructured":"Bais, T. et al. Validation of the mayo imaging classification system for predicting kidney outcomes in ADPKD. Clin. J. Am. Soc. Nephrol. 19, 591\u2013601 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"61887_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ekir.2017.10.004","volume":"3","author":"AL Messchendorp","year":"2018","unstructured":"Messchendorp, A. L. et al. Urinary biomarkers to identify autosomal dominant polycystic kidney disease patients with a high likelihood of disease progression. Kidney Int. Rep. 3, 291\u2013301 (2018).","journal-title":"Kidney Int. Rep."},{"key":"61887_CR38","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1093\/ckj\/sfad118","volume":"16","author":"S Arjune","year":"2023","unstructured":"Arjune, S. et al. Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study. Clin. Kidney J. 16, 2194\u20132204 (2023).","journal-title":"Clin. Kidney J."},{"key":"61887_CR39","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","volume":"320","author":"E Meijer","year":"2018","unstructured":"Meijer, E. et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA 320, 2010\u20132019 (2018).","journal-title":"JAMA"},{"key":"61887_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"61887_CR41","doi-asserted-by":"crossref","unstructured":"Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc. 14, 68\u201385 (2019).","DOI":"10.1038\/s41596-018-0082-x"},{"key":"61887_CR42","doi-asserted-by":"crossref","unstructured":"Rappsilber, J. et al. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc. 2, 1896\u2013906 (2007).","DOI":"10.1038\/nprot.2007.261"},{"key":"61887_CR43","doi-asserted-by":"crossref","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41\u201344 (2020).","DOI":"10.1038\/s41592-019-0638-x"},{"key":"61887_CR44","doi-asserted-by":"crossref","unstructured":"Chambers, M. C J. et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol 30, 918\u2013920 (2012).","DOI":"10.1038\/nbt.2377"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61887-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61887-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61887-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:48:42Z","timestamp":1757256522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61887-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61887"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61887-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5423167\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6646"}}